FAT1 Antibody (Drosophila melanogaster)

Overview

The FAT proteins are members of the Cadherin superfamily homologous to the Drosophila Fat protein that functions as a positive regulator of planar cell polarity in the Drosophila wing. FAT1 is an unusual cadherin that controls cell growth and planar polarity while acting as a tumor suppressor. FAT1 is a proximal element of a signaling pathway that determines both cellular polarity in the plane of the monolayer and directed actin-dependent cell motility. FAT1 is localized at the leading edge of lamellipodia, filopodia and microspike tips where it directly interacts with Ena/VASP proteins to regulate the actin polymerization complex. When targeted to mitochondrial outer leaflets, the cytoplasmic domain of FAT1 recruits components of the actin polymerization machinery sufficient to induce ectopic actin polymerization. FAT1 expression in vascular smooth muscle cells (VSMCs) increases significantly after arterial injury or growth factor stimulation, implicating FAT1 in the control of VSMC functions central to vascular remodeling by facilitating migration and limiting proliferation. FAT1 is also involved in psychic disorders, and its action may be of patho-physiological importance.

This anti-FAT1 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone FAT1-3D7/1, Mouse IgM, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: FAT1
• Format: Purified
• Species reactivity: Drosophila melanogaster
• Applications (listed): ELISA, WB, IF
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone FAT1-3D7/1, Mouse IgM, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

FAT1 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling FAT1 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link FAT1 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• ELISA
• WB
• IF

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.